Ex-Genta Exec Settles SEC Insider Suit Over Melanoma Drug
Law360, Los Angeles (April 21, 2014, 10:13 PM EDT) -- A former Genta Inc. executive and two others agreed to pay penalties to resolve allegations of insider trading on confidential information about the now-defunct drugmaker's disappointing clinical tests for the experimental melanoma drug Genasense, the U.S. Securities and Exchange Commission announced Monday.
The SEC filed a federal complaint Monday against the drugmaker's chief medical officer, Dr. Loretta Itri, along with her longtime friend Dr. Neil T. Moskowitz and his patient Matthew Cashin. The agency alleged that Itri tipped off stockholder Moskowitz a day before bad results from the key clinical trial went public, prompting him to alert Cashin and others, who...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!